Records management services provider Iron Mountain Incorporated (NYSE:IRM) reports Q4 2013 adjusted EPS of $0.15 on revenues of $769 million. Analysts had expected adjusted EPS of $0.22 and revenues of $775 million, according to Capital IQ. Year-ago adjusted EPS was $0.20 on revenues of $758 million.
For 2014, the company reiterated its adjusted EPS and revenue targets. It said adjusted EPS should be in the range of $1.03 – $1.14, with revenues of $3 billion – $3.17 billion. Analysts, on average, are calling for adjusted EPS of $1.11 and revenues of $3.1 billion.
Electricity and natural-gas supply holding company Pepco Holdings (NYSE:POM) reported Q4 results above analysts’ expectations and forecast 2014 earnings in line with the Street view.
Q4 net income rose to $58 million, or $0.23 per share, compared with $43 million, or $0.18 per share, a year earlier.
Earnings from continuing operations excluding one-time items rose to $0.24 per share from $0.17 per share a year earlier, topping analysts’ mean estimate according to Capital IQ of $0.21 per share. Operating revenue climbed 3.3% to $1.09 billion, well above analysts’ mean estimate of $1.3 billion.
For 2014, the company forecast adjusted earnings of $1.12 and $1.27 per share, bracketing analysts’ latest mean estimate of $1.21 per share.
Shares were inactive in recent pre-market trading after closing Thursday at $20.43, in a 52-week range of $18.04 to $22.72.
Shares of IGI Laboratories (NYSEMKT:IG) climbed in Friday’s pre-market session, after the developer of cosmetic and pharmaceutical products for skin conditions late Thursday reported its Q4 loss narrowed sharply on a near tripling in revenue.
IG was up 11% at $4.65 in recent pre-market trading, putting it on track to surpass its 52-week high of $4.34 in the regular session.
The company posted a Q4 net loss attributable to common shareholders of $637,000, or $0.01 per share, from a prior-year loss of $1.2 million, or $0.03 per share. No analyst estimates were available for comparison via Capital IQ. Revenue soared to $6.7 million from $2.3 million.
For 2014, the company expects revenue to increase by 40% to 45% from 2013, and it expects to be profitable, although the company noted it plans to “at least double” research-and-development spending to accelerate the growth of its pipeline.
The company plans to file at least 10 abbreviated new drug applications in 2014. It currently had 13 filings pending with the Food and Drug Administration.